Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Surveyed U.S. psychiatrists would prescribe EnVivo Pharmaceuticals/Bayer HealthCare/Mitsubishi Tanabe Pharma’s encenicline to 25 percent of their patients with cognitive impairment associated with schizophrenia ... Learn More
Join us live on May 15, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
Come join us for an exciting one-day seminar.
Walk away with expert insights on ACOs,
Exchanges and the impact of Healthcare Reform.
View the Agenda | Meet our expert speakers
April 23, 2014
Eravacycline’s Improvements in Efficacy and Delivery Over Competitors will Drive Uptake for the Treatment of Gram-Negative Infections due to Multidrug-Resistant Enterobacteriaceae
April 22, 2014
Nephrologists Indicate that Improvement in Renal Anemia Parameters is One of the Top Three Efficacy Attributes for a New Hyperphosphatemia Treatment
April 21, 2014
For Treatment of Ulcerative Colitis (UC), Great Opportunity Exists for Vedolizumab in the U.S. and EU5 Market, Owing to its Novel Mechanism of Action and Promising Efficacy
Asthma (Moderate to Severe)
Although several effective anti-inflammatory agents and bronchodilators are currently available for controlling disease... Read More
Chronic Obstructive Pulmonary Disease
Treatment of chronic obstructive pulmonary disease (COPD) is dominated by bronchodilators, and polypharmacy is... Read More
The availability of tumor necrosis factor alpha (TNF-a) inhibitors as therapeutic options has revolutionized the... Read More